Riverview Trust Company’s Biogen BIIB Stock Holding History

Riverview Trust Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-286	Closed	-$39.1K	–	260
2025 Q1	$39.1K	Buy	+286	New	+$40.9K	0.04%	258
2024 Q4	–	Sell	-93	Closed	-$18K	–	839
2024 Q3	$18K	Buy	+93	New	+$19.5K	0.02%	525
2024 Q2	–	Sell	-93	Closed	-$20.1K	–	632
2024 Q1	$20.1K	Buy	+93	New	+$21.8K	0.02%	478
2023 Q4	–	Sell	-47	Closed	-$12.1K	–	151
2023 Q3	$12.1K	Hold	47	–	–	0.01%	635
2023 Q2	$13.4K	Hold	47	–	–	0.01%	608
2023 Q1	$13.1K	Hold	47	–	–	0.01%	599
2022 Q4	$13K	Buy	+47	New	+$13.3K	0.01%	545
2022 Q3	–	Sell	-105	Closed	-$21K	–	732
2022 Q2	$21K	Buy	105 +30	+40%	+$6.13K	0.02%	374
2022 Q1	$16K	Buy	+75	New	+$16.3K	0.01%	577

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Riverview Trust Company's BIIB Position: Q2 2025 in Review

Riverview Trust Company sold out of Biogen (BIIB) in Q2 2025, closing a stake of 286 shares — an estimated $39.1K sold.

Riverview Trust Company first reported a position in BIIB in Q1 2022 and held it in 9 quarters. The position peaked at $39.1K in Q1 2025. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

Riverview Trust Company reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
Riverview Trust Company sold 286 Biogen shares in Q2 2025, an estimated $39.1K.
Riverview Trust Company first reported a position in Biogen in Q1 2022 and held it in 9 quarters.
Riverview Trust Company's Biogen position peaked at $39.1K in Q1 2025.
866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.